1465809-36-2
Chemical Structure
Zifogaptide
- CAS No.: 1465809-36-2
- Formula:C166H263N51O37S
- Molecular Weight:3597.25
SMILES: O=C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N9[C@@H](CCC9)C(N[C@@H](CCCNC(N)=N)C(N%10[C@@H](CCC%10)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)NC(CCCCCNC(CCCC[C@@H]%11SC[C@]([C@]%11([H])N%12)([H])NC%12=O)=O)=O
Biological Activity: Zifogaptide is a gap junction protein channel regulator. Zifogaptide mimics the PDZ-binding motif at the C-terminal of Claudin C and competitively interferes with the interaction between Claudin–TJP1 (ZO-1) scaffold. Zifogaptide can promote epithelial cell migration, reduce scar formation, and accelerate wound healing. Zifogaptide can be used for radiation dermatitis, skin injuries, etc[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zifogaptide | 98.97% | Zifogaptide is a gap junction protein channel regulator. Zifogaptide mimics the PDZ-binding motif at the C-terminal of Claudin C and competitively interferes with the interaction between Claudin–TJP1 (ZO-1) scaffold. Zifogaptide can promote epithelial cell migration, reduce scar formation, and accelerate wound healing. Zifogaptide can be used for radiation dermatitis, skin injuries, etc. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Neuromedin (B-30) | Neuromedin B-30 is the neuropeptide, which is orignally isolated from porcine brain and spinal cord. , and may exhibit activity in stimulating smooth-muscle. Neuromedin B causes local vasodilation, increases vascular permeability and local hyperalgesia, thereby participating in neurogenic inflammation. Neuromedin B regulates appetite, body temperature, and behavioral responses to stress. Neuromedin B is also involved in regulating smooth muscle contraction and secretory function in the gastrointestinal tract. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BIMAX1 | BIMAX1 is a tool peptide used in experiments to examine the interaction of RBBP4 with importin β1 and the effects on the nuclear import pathway. BIMAX1 can be used to study the role of RBBP4 in regulating nuclear import efficiency and cellular senescence. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Apelin-36(human) | 98.01% | Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IMG-2005 | IMG-2005 is a TLR signaling pathway inhibitor. IMG-2005 mimics the Toll/interleukin-1 receptor (TIR) domain of MyD88, thereby preventing its homodimerization, which causes damage to tracheal epithelial cells and triggers pulmonary immune diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pepinh-MYD | 99.85% | Pepinh-MYD is a MyD88 inhibitor that contains a domain sequence from MyD88 TIR and a protein transduction sequence, enabling it to penetrate the cell membrane. Pepinh-MYD interferes with MyD88-mediated TLR signaling pathways, thereby inhibiting related immune responses. It holds potential for studying the role of MyD88 in viral infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RANK-derived TRAF6 inhibitor | RANK-derived TRAF6 inhibitor is a TRAF6 inhibitor peptide that blocks the interaction of TRAF6 and LMP1 with an IC50 of 177 nM. RANK-derived TRAF6 inhibitor causes a severe reduction in cell viability in the LMP1-dependent lymphoblastoid cell lines (LCLs). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PTD-N5-1 | PTD-N5-1 is an IRF5 inhibitory peptide. PTD-N5-1 blocks the activation of IRF5. PTD-N5-1 inhibits β-glucan-induced IL-12 production in bone marrow-derived dendritic cells pre-stimulated with IFN-γ. PTD-N5-1 reduces the levels of IL-12 and IFN-γ in the kidneys of mice with Candida albicans infection. PTD-N5-1 is applicable to the research of Candida albicans infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ACT1 | ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen (HY-13757A) and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Biotinyl-ACTH (1-39) (human) | Biotinyl-ACTH (1-39) (human) is abiotinylated Adrenocorticotropic Hormone (ACTH) (1-39), human (HY-P1211). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ACTH (7-38) (human) | 99.57% | ACTH (7-38) (human) is the 7-38 fragment of human ACTH (1-39). human ACTH (1-39), known as a corticotropin inhibitory peptide (CIP), is an antagonist of the ACTH receptor and has no any corticosteroid activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
